Tenaya Therapeutics (TNYA) Income from Continuing Operations (2020 - 2026)
Tenaya Therapeutics' (TNYA) quarterly Income from Continuing Operations came in at 19272000.0 in Q1 2026, up 28.26% year-on-year from 15025627.12 in Q1 2025, and up 4.48% quarter-over-quarter from 20175000.0 in Q4 2025.
Tenaya Therapeutics (TNYA) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Tenaya Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 19272000.0 for Q1 2026.
- On a quarterly basis, Income from Continuing Operations rose 28.26% year-over-year to 19272000.0 in Q1 2026; TTM through Mar 2026 was 83005000.0, a 21.52% increase from a year earlier, with the FY2025 full-year figure at 90597000.0, up 18.48% from the prior year.
- Income from Continuing Operations grew to 19272000.0 in Q1 2026 per TNYA's latest filing, from 20175000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 19272000.0 in Q1 2026 and bottomed at 33516000.0 in Q4 2022.
- The 5-year median for Income from Continuing Operations is 29143000.0 (2023), against an average of 27573352.94.
- Across the five-year window, Income from Continuing Operations tumbled 137.1% in 2022 and climbed 28.26% in 2026, its largest moves.
- Year by year, Income from Continuing Operations stood at 33516000.0 in 2022, then gained by 10.68% to 29935000.0 in 2023, then grew by 20.37% to 23836000.0 in 2024, then climbed by 15.36% to 20175000.0 in 2025, then grew by 4.48% to 19272000.0 in 2026.
- Per Business Quant, the three latest TNYA Income from Continuing Operations figures stand at 19272000.0 (Q1 2026), 20175000.0 (Q4 2025), and 20275000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Tenaya Therapeutics | 167.00 Mn | 167.00 Mn | - | -19.27 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -19.27 Mn |
| Dec 31, 2025 | -20.18 Mn |
| Sep 30, 2025 | -20.28 Mn |
| Jun 30, 2025 | -23.28 Mn |
| Mar 31, 2025 | -26.86 Mn |
| Dec 31, 2024 | -23.84 Mn |
| Sep 30, 2024 | -25.63 Mn |
| Jun 30, 2024 | -29.43 Mn |
| Mar 31, 2024 | -32.23 Mn |
| Dec 31, 2023 | -29.94 Mn |
| Sep 30, 2023 | -29.14 Mn |
| Jun 30, 2023 | -33.27 Mn |
| Mar 31, 2023 | -31.74 Mn |
| Dec 31, 2022 | -33.52 Mn |
| Sep 30, 2022 | -30.70 Mn |
| Jun 30, 2022 | -28.40 Mn |
| Mar 31, 2022 | -31.06 Mn |
| Dec 31, 2021 | -26.15 Mn |
| Sep 30, 2021 | -18.26 Mn |
| Jun 30, 2021 | -15.21 Mn |